Preliminary results of sintilimab (Sin) plus bevacizumab (Bev) in recurrent/persistent ovarian clear cell carcinoma (INOVA): A multicenter, single-arm, phase II trial

被引：9

作者：

Liu, X. ^{[1
]}

Xia, B. ^{[2
]}

Zhang, W. ^{[3
]}

Sun, L. ^{[4
]}

Feng, C. ^{[5
]}

Huang, Y. ^{[6
]}

Gao, Y. ^{[7
]}

Jiang, J. ^{[8
]}

Li, G. ^{[9
]}

Gao, Q. ^{[1
]}

机构：

[1] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Gynaecol Oncol, Wuhan, Peoples R China

[2] Univ Sci & Technol China, Div Life Sci & Med, Affiliated Hosp 1, Hefei, Peoples R China

[3] Huazhong Univ Sci & Technol, Natl Clin Res Ctr Obstet & Gynaecol, Canc Biol Res Ctr, Tongji Med Coll,Tongji Hosp,Key Lab,Minist Educ, Wuhan, Peoples R China

[4] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Dept Gynaecol,Canc Hosp, Beijing, Peoples R China

[5] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Radiol, Tongji Med Coll, Wuhan, Peoples R China

[6] Huazhong Univ Sci & Technol, Hubei Canc Hosp, Dept Gynaecol Oncol, Tongji Med Coll, Wuhan, Peoples R China

[7] Peking Univ Canc Hosp & Inst, Dept Gynaecol Oncol, Minist Educ, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China

[8] Shandong Univ, Qilu Hosp, Dept Obstet & Gynaecol, Jinan, Peoples R China

[9] Huazhong Univ Sci & Technol, Union Hosp, Dept Gynaecol Oncol, Tongji Med Coll, Wuhan, Hubei, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.650

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

522MO

引用

页码：S783 / S783

页数：1